• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Evaluation of drug intake during pregnancy in the Hungarian Case-Control Surveillance of Congenital Anomalies.

作者信息

Czeizel A, Rácz J

机构信息

Department of Human Genetics and Teratology, National Institute of Hygiene-WHO Collaborating Centre for the Community Control of Hereditary Diseases, Budapest, Hungary.

出版信息

Teratology. 1990 Nov;42(5):505-12. doi: 10.1002/tera.1420420507.

DOI:10.1002/tera.1420420507
PMID:2148987
Abstract

The data of the Hungarian Case-Control Surveillance of Congenital Anomalies, 1980-1987, were evaluated concerning drug intake during pregnancy in 10,698 index patients, 21,546 negative controls, and 828 positive controls (Down syndrome). Excluding pregnancy supplements, the proportion of no drug use was about 30% and the mean number of drugs used was 2.0 in the negative control group. These figures did not differ significantly from data of study and positive control groups. The analysis of most commonly used drugs indicated an extremely high proportion of hormonal support therapy. The teratogenic effect of several human teratogenic drugs was confirmed. However, their use is relatively rare and their attributable risk within the etiology of congenital anomalies is low, at about 0.3-1.0%. At present the teratogenic risk of drugs in humans is exaggerated and it has several unfortunate consequences: negligence in necessary drug use, unnecessary anxiety in pregnant women, and termination of planned pregnancies without any reasonable cause.

摘要

相似文献

1
Evaluation of drug intake during pregnancy in the Hungarian Case-Control Surveillance of Congenital Anomalies.
Teratology. 1990 Nov;42(5):505-12. doi: 10.1002/tera.1420420507.
2
[Evaluation of the effect of drug intake during pregnancy based on the Monitoring Surveillance of the Pathogenesis of Congenital Anomalies].基于先天性畸形发病监测的孕期用药效果评估
Orv Hetil. 1992 Feb 16;133(7):407-8, 413-5.
3
The estimation of human teratogenic/fetotoxic risk of exposures to drugs on the basis of Hungarian experience: a critical evaluation of clinical and epidemiological models of human teratology.基于匈牙利经验评估药物暴露致人类致畸/胚胎毒性风险:对人类畸形学临床和流行病学模型的批判性评价。
Expert Opin Drug Saf. 2009 May;8(3):283-303. doi: 10.1517/14740330902916459.
4
Description and mission evaluation of the Hungarian case-control surveillance of congenital abnormalities, 1980-1996.1980 - 1996年匈牙利先天性异常病例对照监测的描述与任务评估
Teratology. 2001 May;63(5):176-85. doi: 10.1002/tera.1032.
5
Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy.基于人群的孕期羟孕酮治疗致畸性病例对照研究。
Congenit Anom (Kyoto). 2006 Dec;46(4):194-8. doi: 10.1111/j.1741-4520.2006.00128.x.
6
Teratogenic potential of pholedrine: a sympathomimetic vasoconstrictive drug - a population-based case-control study.去氧肾上腺素的致畸潜力:一种拟交感神经血管收缩药物——一项基于人群的病例对照研究。
Congenit Anom (Kyoto). 2010 Jun;50(2):122-8. doi: 10.1111/j.1741-4520.2010.00276.x. Epub 2010 Feb 22.
7
[The possible teratogenic effect of levamisole treatment during pregnancy].[孕期左旋咪唑治疗可能的致畸作用]
Orv Hetil. 2005 Dec 4;146(49):2499-500.
8
Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population-based, case-control study.
Am J Obstet Gynecol. 2001 May;184(6):1289-96. doi: 10.1067/mob.2001.113905.
9
The role of pharmacoepidemiology in pharmacovigilance: rational drug use in pregnancy.药物流行病学在药物警戒中的作用:孕期合理用药
Pharmacoepidemiol Drug Saf. 1999 Apr;8 Suppl 1:S55-61. doi: 10.1002/(SICI)1099-1557(199904)8:1+<S55::AID-PDS404>3.0.CO;2-1.
10
Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a case-time-control study.孕期使用苯妥英钠、苯巴比妥或地西泮与先天性异常风险:一项病例-时间-对照研究
Pharmacoepidemiol Drug Saf. 2007 Feb;16(2):181-8. doi: 10.1002/pds.1288.

引用本文的文献

1
Doxycycline use and adverse pregnancy or neonatal outcomes: A descriptive study using the United States Food and Drug Administration Adverse Event Reporting System database.强力霉素的使用与不良妊娠或新生儿结局:一项使用美国食品药品监督管理局不良事件报告系统数据库的描述性研究。
Health Sci Rep. 2022 Nov 14;5(6):e931. doi: 10.1002/hsr2.931. eCollection 2022 Nov.
2
Lithium Use in Pregnancy and the Risk of Cardiac Malformations.孕期使用锂与心脏畸形风险
N Engl J Med. 2017 Jun 8;376(23):2245-2254. doi: 10.1056/NEJMoa1612222.
3
[Affective disorders during pregnancy : Therapy with antidepressants and mood stabilizers].
孕期情感障碍:抗抑郁药和心境稳定剂治疗
Nervenarzt. 2016 Sep;87(9):955-66. doi: 10.1007/s00115-016-0194-x.
4
Lithium During Pregnancy : Drug Effects and Their Therapeutic Implications.锂在孕期的应用:药物作用及其治疗学意义。
CNS Drugs. 1998 Apr;9(4):261-9. doi: 10.2165/00023210-199809040-00002.
5
Revisiting doxycycline in pregnancy and early childhood--time to rebuild its reputation?重新审视孕期及幼儿期使用强力霉素——是时候重塑其声誉了吗?
Expert Opin Drug Saf. 2016;15(3):367-82. doi: 10.1517/14740338.2016.1133584. Epub 2016 Jan 25.
6
A Possible Association between Oral Aminophylline Treatment during Pregnancy and Skeletal Congenital Abnormalities.妊娠期口服氨茶碱治疗与骨骼先天畸形的相关性研究。
Clin Drug Investig. 2003;23(12):803-16. doi: 10.2165/00044011-200323120-00005.
7
Short-Term Oral Diazepam Treatment during Pregnancy : A Population-Based Teratological Case-Control Study.妊娠期短期口服地西泮治疗:基于人群的致畸病例对照研究。
Clin Drug Investig. 2003;23(7):451-62. doi: 10.2165/00044011-200323070-00004.
8
A population-based case-control teratologic study of oral dipyrone treatment during pregnancy.
Drug Saf. 2007;30(1):59-70. doi: 10.2165/00002018-200730010-00006.
9
Safe prescribing practices in pregnancy and lactation.孕期及哺乳期的安全用药规范
J Midwifery Womens Health. 2002 Nov-Dec;47(6):409-21. doi: 10.1016/s1526-9523(02)00324-0.
10
How do we best detect toxic effects of drugs taken during pregnancy? A EuroMap paper.我们如何才能最好地检测孕期用药的毒性作用?一篇欧洲地图组织的论文。
Drug Saf. 2002;25(1):21-32. doi: 10.2165/00002018-200225010-00003.